Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVJF) Short-Term Debt issuances (2016 - 2023)

Historic Short-Term Debt issuances for Teva Pharmaceutical Industries (TEVJF) over the last 12 years, with Q3 2023 value amounting to $700.0 million.

  • Teva Pharmaceutical Industries' Short-Term Debt issuances changed N/A to $700.0 million in Q3 2023 from the same period last year, while for Dec 2024 it was $700.0 million, marking a year-over-year decrease of 2222.22%. This contributed to the annual value of $700.0 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Short-Term Debt issuances of $700.0 million as of Q3 2023.
  • Teva Pharmaceutical Industries' Short-Term Debt issuances' 5-year high stood at $700.0 million during Q3 2023, with a 5-year trough of -$1.0 million in Q1 2019.
  • Over the past 4 years, Teva Pharmaceutical Industries' median Short-Term Debt issuances value was $200.0 million (recorded in 2021), while the average stood at $245.6 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Short-Term Debt issuances surged by 990000.0% in 2019, and later plummeted by 3730.41% in 2021.
  • Over the past 4 years, Teva Pharmaceutical Industries' Short-Term Debt issuances (Quarter) stood at $404.0 million in 2019, then fell by 21.04% to $319.0 million in 2020, then tumbled by 37.3% to $200.0 million in 2021, then soared by 250.0% to $700.0 million in 2023.
  • Its last three reported values are $700.0 million in Q3 2023, $200.0 million for Q4 2021, and $319.0 million during Q4 2020.